Merck/Schering Zetia Effects On Triglycerides, HDL-C Questioned In Review

FDA and Merck/Schering-Plough reached a middle ground on Zetia's indication, allowing the "small" effects on triglycerides and HDL-cholesterol to be described in the clinical studies section of labeling but not in the indication, NDA review documents show